Turn your website into a research center by adding headline feeds and a magazine article search engine covering topics relevant to your site.

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Medical

Magazine articles on health care providers, pharmaceutical companies, and medical technology.

See Also

Health Health / Illness, Injury & Treatments Health / Medical Practice Science & Technology / Biology & Life Sciences

Current Medical Articles

BusinessWeek November 19, 2009 Catherine Arnst	Why Drugmakers Don't Twitter The FDA has so far failed to craft rules clarifying how pharmaceutical companies can participate in online discussions.
The Motley Fool November 19, 2009 Brian Orelli	Pfizer Dodges a Bullet The drugmaker slips through an advisory committee unscathed.
The Motley Fool November 19, 2009 Brian Orelli	This Stock Is a Train Wreck Genzyme's string of missteps has investors nervous.
The Motley Fool November 19, 2009 Brian Orelli	Pfizer's Generic Growth, With a Side of Sashimi A move into Japan isn't a bad idea, but it isn't going to save the company either.
Chemistry World November 18, 2009 Sarah Houlton	A pharmaceutical named desire A new drug being developed by Boehringer Ingelheim could give a boost to the sex drive of women with low libido.
The Motley Fool November 18, 2009 Brian Orelli	Your Heart or Your Stomach? It must be disappointing to know that a label change on another drug -- one that isn't even your competition -- is going to hurt sales, but that's the position that Procter & Gamble and AstraZeneca find themselves in.
The Motley Fool November 18, 2009 Brian Orelli	Drug Lowers Cholesterol; Stock Follows ISIS has a hard time at American Heart Association despite good efficacy data.
The Motley Fool November 18, 2009 Brian Orelli	VIVUS Gets a Spark A new erectile-dysfunction drug shows promise.
The Motley Fool November 17, 2009 Brian Orelli	Up 80%, It's Time to Sell Bristol-Myers to Mead Johnson: It's time to walk on your own. Investors will have an option of exchanging some or all of their Bristol-Myers shares for shares in Mead Johnson for a slight discount
The Motley Fool November 17, 2009 Brian Orelli	This Partnership Is Smoking! Glaxo and Nabi team up for smokers who want to quit. Let's just hope they don't flame out in phase 3 trials.
The Motley Fool November 17, 2009 Dave Mock	A Big Upgrade for Sanofi-Aventis This bullish call comes from more than just one analyst.
The Motley Fool November 16, 2009 Brian Orelli	Music to Health-Care Investors' Ears Are faster FDA review times coming?
The Motley Fool November 16, 2009 Amanda B. Kish	The Hottest Sector for 2010 It's hard to argue that the potential benefits to this sector won't be significant if health care reform does work its way through. The time to stock up on high-quality health-care names is now.
The Motley Fool November 16, 2009 Brian Orelli	Abbott Puts a Nail in Merck's Coffin There's a clear winner from the American Heart Association conference.
CRM November 2009 Lauren McKay	Pharmaceuticals -- CRM Undergoes an Experimental New Treatment An older CRM vertical gets a new dose of on-demand technology.
The Motley Fool November 13, 2009 Brian Orelli	Abbott: Brave or Stupid? Abbott Labs announces the acquisition of PanGenetics' pain drug PG110, which is still in phase 1 trials.
The Motley Fool November 13, 2009 Brian Orelli	Questioning Pfizer's Integrity Pfizer's epilepsy drug Neurontin has had generic competition for a few years, but it's still plaguing the pharmaceutical giant.
BusinessWeek November 12, 2009 Catherine Arnst	10 Ways to Cut Health-Care Costs Right Now Employers and hospitals don't have to wait for Congress to address inefficiencies and waste.
The Motley Fool November 12, 2009 Brian Orelli	How Do You Say 'Drug Development' in Mandarin? Drug giant Novartis announces that it's heading to China in a big way.
The Motley Fool November 12, 2009 Brian Orelli	The Life-and-Death Situation That Isn't Branded-drug makers aren't playing fair because they refuse to sell samples to generic drug makers.
The Motley Fool November 12, 2009 Kris Eddy	Drug Companies Should Think Smaller Sanofi-aventis looks to break R&D into smaller chunks; their collaboration with Regeneron Pharmaceuticals is a good example of the new strategy.
The Motley Fool November 11, 2009 Robert Steyer	There Will Be Blood (Plasma) Talecris Biotherapeutics Holdings introduces itself to investors with a bloody good third quarter.
The Motley Fool November 11, 2009 Jim Mueller	This Company Is a Value Stock! Isn't It? A look at Boston Scientific leads to conflicting conclusions.
The Motley Fool November 11, 2009 Brian Orelli	Now That's What I Call a Drug Deal Investors are regenerating their interest in Regeneron Pharmaceuticals after it extended its drug-discovery pact with sanofi-aventis.
The Motley Fool November 10, 2009 Brian Orelli	Small Acquisitions and the Road to Success Bristol-Myers is taking a different route to bulk up. It announced licensing of a phase 2 rheumatoid arthritis drug, ALD518, from privately held Alder Biopharmaceuticals.
The Motley Fool November 10, 2009 Brian Orelli	3 Companies Looking for Gratitude Early These three small drug companies all have PDUFA dates in the next week: Cadence Pharmaceuticals... NeurogesX... Genzyme...
The Motley Fool November 9, 2009 Brian Orelli	Guidant: The Gift That Keeps on Giving And not in the good way. Last year, Boston Scientific took a whopping $2.7 billion goodwill writedown because it had to downgrade the value of what it got in acquiring Guidant.
The Motley Fool November 9, 2009 Brian Orelli	Health-Care Reform: A Tale of Two Chambers Halfway done, but the battle is just heating up.
The Motley Fool November 9, 2009 Dave Mock	A Big Upgrade for Gilead Sciences The biopharmaceutical company moves up to a five star rating from Motley Fool analysts.
BusinessWeek November 4, 2009 Arlene Weintraub	Ask Your Doctor If This Ad Is Right for You The drug industry is spending billions on TV ads, but they may be scaring consumers away
HBS Working Knowledge November 5, 2009 Michel Anteby	A Market for Human Cadavers in All but Name? Addressing the shortage of cadavers for medical education and training, Harvard Business School professor Michel Anteby discusses issues around establishing a market for cadavers.
The Motley Fool November 5, 2009 Brian Orelli	Slow Down There, Merck Merck CEO Richard Clark says his company is looking to do more deals than ever, perhaps "even try to double" the current rate of 50 per year.
Chemistry World November 4, 2009 Phil Taylor	New treatment hope for lupus patients GlaxoSmithKline and Human Genome Sciences' Benlysta (belimumab), works by blocking the production of autoantibodies by plasma B-cells, the immune system's primary antibody-producing cells.
The Motley Fool November 4, 2009 Brian Orelli	An Ode to Schering-Plough Mergers and acquisitions in the pharmaceutical industry are cataloged in a poem.
The Motley Fool November 4, 2009 Brian Orelli	This One Is Thriving in a Recession Saving customers money makes it easy for Medco.
The Motley Fool November 3, 2009 Brian Orelli	Nice Quarter, Teva. What Will You Buy Next? Branded or generic, it's always a tough call.
The Motley Fool November 3, 2009 Brian Orelli	A Little Distracted, Are You, Merck? The FDA rejects its latest application.
The Motley Fool November 3, 2009 Rich Smith	Is BABY Back? Natus Medical beat earnings, but can it continue to top the S&P 500?
The Motley Fool November 3, 2009 Brian Orelli	Amylin Scores a Hat Trick Amylin Pharmaceuticals got a triple dose of good news over the weekend.
The Motley Fool November 3, 2009 Rich Smith	This Just In: Upgrades and Downgrades Needham suspends clinical trial of buying Geron.
Chemistry World October 23, 2009 Matt Wilkinson	What's in a pill? Buying cheap drugs over the internet is well known to be a risky business. But the sinister menace of the 'falsified' active pharmaceutical ingredient gets far less publicity.
Fast Company November 2009 David H. Freedman	The Gene Bubble: Why We Still Aren't Disease-Free When the human genome was first sequenced nearly a decade ago, the world lit up with talk about how new gene-specific drugs would help us cheat death. Well, the verdict is in: Keep eating those greens.
Fast Company November 2009 Stephanie Schomer	Lost Dollars in Gene Research Billions of R&D dollars flowed to companies promising to cure our ills. Most of those companies are now dead or forgotten.
MyBusiness Oct/Nov 2009	What's On Your Mind? A look at some of the public opinion polls shows what was on your mind this summer.
MyBusiness Oct/Nov 2009 Bob Graboyes	Beyond 2009: The Three Big M's No one should underestimate their power of Medicare, Medicaid and malpractice to make or break small businesses in the not-too-distant future.
There are 6209 old articles available for this category.